


Express Mail No.: EV 871034503 US
Date of Deposit: October 11, 2007

Page 1 of 1
Attorney Docket No.: 26505-514 NATL



Please type a plus sign (+) in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 149/PTO	Application Number	10/590,782
	Filing Date	February 25, 2005
	First Named Inventor	Farmer
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	26505-514 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C28	Ban et al., "The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 Å Resolution," <i>Science</i> , 289:905-920 (2000)
	C29	Brickner, S.J., "Oxazolidinone Antibacterial Agents," <i>Current Pharm. Design</i> , 2(2):174-194 (1996)
	C30	Franceschi et al., "Structure-Based Drug Design Meets the Ribosome," <i>Biochem. Pharmacol.</i> , 71:1016-1025 (2006)
	C31	Mutak, S., "Azalides from Azithromycin to New Azalide Derivatives," <i>J. Antibiot.</i> , 60(2):85-122 (2007)
	C32	Pal, S., "A Journey Across the Sequential Development of Macrolides and Ketolides Related to Erythromycin," <i>Tetrahedron</i> , 62:3171-3200 (2006)
	C33	Sutcliffe, J.A., "The Search for New Antibiotics Targeting the 50S Ribozyme," <i>ASM News</i> , 70(11):513-519 (2004)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.